This resolution expresses support for designating the week of May 4-10, 2025, as Tardive Dyskinesia Awareness Week to educate the public and healthcare providers about this involuntary movement disorder.
Scott Peters
Representative
CA-50
This resolution expresses the support of the House of Representatives for designating the week of May 4–10, 2025, as "Tardive Dyskinesia Awareness Week." The measure aims to raise public and medical community awareness about tardive dyskinesia (TD), an involuntary movement disorder often caused by long-term use of certain medications. By promoting education, the bill encourages better monitoring and diagnosis for the estimated 600,000 Americans currently affected by this condition.
This resolution from the House of Representatives is straightforward: it officially supports designating the week of May 4–10, 2025, as "Tardive Dyskinesia Awareness Week." While a resolution supporting an awareness week might sound like standard political filler, the underlying issue—Tardive Dyskinesia (TD)—is a serious public health concern that affects hundreds of thousands of people, most of whom don't even know they have it. This move is about getting essential information out to both patients and healthcare providers.
TD is an involuntary movement disorder that can be a side effect of long-term use of certain medications, primarily antipsychotics used for serious mental health conditions and some antiemetics used for gut issues. The resolution emphasizes that TD, which involves uncontrollable movements in the face, body, or limbs, affects an estimated 600,000 people in the U.S. Here’s the kicker: about 65% of those people are currently undiagnosed. Think about that: two out of three people dealing with this side effect are walking around without a proper diagnosis, which is why this awareness push is so critical.
If you or someone you care about manages a mental health condition or a chronic digestive issue requiring medication, this resolution is speaking directly to your healthcare routine. The text points out that the American Psychiatric Association already recommends regular screening for TD in patients taking these at-risk medications. This resolution acts as a congressional nudge, encouraging providers to actually follow those guidelines. For the patient, this means your doctor should be actively looking for subtle signs of TD during checkups, especially if you’ve been on one of those dopamine-blocking drugs for a while. Early detection is key, especially since FDA-approved treatments for TD are now available.
This resolution doesn't create new laws or mandate spending, but its power lies in refocusing attention. By formally recognizing TD Awareness Week, Congress is essentially putting a spotlight on a condition that often gets overlooked or misdiagnosed. The goal is to encourage public education, which could translate into patients knowing to ask their doctors about TD risk or recognizing symptoms in themselves or their loved ones. If this effort leads to even a small fraction of those 65% undiagnosed individuals getting screened and treated, it represents a huge win for improving quality of life for people already managing complex health challenges.